ADMA Biologics-Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know

Group 1 - Adma Biologics (ADMA) closed at $21.31, with a +0.38% change from the previous day, outperforming the S&P 500's gain of 0.13% [1] - Over the past month, ADMA shares have appreciated by 3.01%, while the Medical sector lost 8.46% and the S&P 500 lost 6.3% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of$ 0.16, reflecting a 100% increase from the same quarter last year [2] - Revenue is forecasted to be $119.1 million, indicating a growth of 45.46% compared to the corresponding quarter of the prior year [2] Group 3 - Full-year Zacks Consensus Estimates predict earnings of$ 0.71 per share and revenue of $495.8 million, representing year-over-year changes of +44.9% and +16.26%, respectively [3] - Recent adjustments to analyst estimates for Adma Biologics indicate positive sentiment regarding the company's business and profitability [3] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 deliver an average annual return of +25% since 1988 [5] - Over the past month, the Zacks Consensus EPS estimate for Adma Biologics has increased by 2.16%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Group 5 - Adma Biologics has a Forward P/E ratio of 29.9, which is a premium compared to the industry average Forward P/E of 15.68 [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6]